1,2,3-TRIAZOLOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a compound as shown in formula I capable of inhibiting inflammasome nucleotide oligomerization domain-like receptor protein 3 (NLRP3) and inhibiting the secretion of interleukin-1β (IL-1β), and a preparation method therefor. ELISA experiments show that this type of compound can signifi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHU, Lei, HOU, Wenbin, YU, Jingcheng, GOU, Wenfeng, BI, Changfen, CHEN, Leyuan, YE, Caiying, TIAN, Chen, GUO, Jianghong, JIA, Jianhua, NING, Hongxin, ZHOU, Yongting, WEI, Huiqiang, LI, Yiliang, MU, Ruixu, YU, Jiang
Format:	Patent
Sprache:	chi ; eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed are a compound as shown in formula I capable of inhibiting inflammasome nucleotide oligomerization domain-like receptor protein 3 (NLRP3) and inhibiting the secretion of interleukin-1β (IL-1β), and a preparation method therefor. ELISA experiments show that this type of compound can significantly inhibit the activity of NLRP3 and reduce the expression of the inflammatory factor IL-1β downstream of NLRP3. The compound of formula I is expected to become a new anti-inflammatory drug and a drug for treating autoimmune diseases. L'invention concerne un composé tel que représenté dans la formule I capable d'inhiber l'inflammasome de la protéine 3 du récepteur de type domaine d'oligomérisation des nucléotides (NLRP3) et d'inhiber la sécrétion de l'interleukine-1β (IL-1β), et son procédé de préparation. Des expériences ELISA montrent que ce type de composés peut inhiber de manière significative l'activité de NLRP3 et réduire l'expression du facteur inflammatoire IL-1β en aval de NLRP3. Le composé de formule